by Admin | Sep 13, 2024 | Portfolio News
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies,...
by Admin | Jul 26, 2024 | Portfolio News
Financing Fuels the Company’s Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic’s Appointment Positions Imperative Care for Long Term Success and Scale July 25, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS...
by Admin | Jul 23, 2024 | Portfolio News
Tulavi Therapeutics has received a de novo clearance from the FDA for a surgical kit designed to help reduce long-term phantom limb pains among people who have had an amputation. The Allay nerve cap system includes an absorbable hydrogel that encases the end of...
by Admin | Jul 23, 2024 | Portfolio News
Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug...
by Admin | Jul 11, 2024 | Portfolio News
First-in-human Phase 1a/1b clinical trial will evaluate orally available, RGT-61159 designed to selectively target MYB RNA and inhibit oncogenic MYB protein production Preclinical data supporting the clinical trial were recently presented at the American Society...
by Admin | Jun 25, 2024 | Portfolio News
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight Company is developing a new class...